The portfolio includes approximately 45 commercial products, four pipeline products and 40 approved non-marketed products, including a number of generic products focused on women’s health.
Natco launched pomalidomide under their brand NAT-POMALIDOMIDE in strengths of 1 mg, 2 mg, 3 mg and 4 mg capsules
Olaparib is indicated primarily for certain forms of ovarian, breast, pancreatic, and prostate cancer
The respective product approval is based on Revlimid Capsules, 5mg, 10mg, 15mg, 25mg and 2.5mg, 20mg as a reference product
BDRs journey for the treatment of Prostate Cancer started with Abiratarone Acetate, then Leuprolide Acetate followed by Enzalutamide and, then Degarelix and Triptorelin.
Diclofenac Sodium Topical Solution, 2% w/w (RLD PENNSAID) had estimated annual sales of US $509 million in the US (IQVIA MAT October 2022)
Spiro will be responsible for the overall strategy, implementation and growth of Lupin’s U.S. Generics business
This product is based on Osmotic Controlled Release Oral Delivery System technology
He has over two decades of rich experience in management consulting, advising and transforming leading generic pharmaceutical companies in India and global markets
Pfizer’s Paxlovid is approved by US FDA for COVID treatment
Subscribe To Our Newsletter & Stay Updated
